Inactive Instrument

Biotoscana Investments S.A.

GBIO33

BRGBIOBDR008

Biotoscana Investments S.A.(BOVESPA:GBIO33) dropped from S&P Global BMI Index

August 20, 2020 at 12:00 am EDT

Latest news about Biotoscana Investments S.A.

Biotoscana Investments S.A.(BOVESPA:GBIO33) dropped from S&P Global BMI Index	20-08-20	CI
1178991 Canada Inc. completed the acquisition of the remaining 48.8% stake in Biotoscana Investments S.A. approximately BRL 540 million.	20-08-13	CI
Biotoscana Investments S.A. Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-08-13	CI
Biotoscana Investments S.A. Reports Earnings Results for the First Quarter Ended March 31, 2020	20-06-26	CI
Tranche Update on Biotoscana Investments S.A.'s Equity Buyback Plan announced on August 14, 2018.	20-03-31	CI
Biotoscana Investments S.A. Reports Earnings Results for the Full Year Ended December 31, 2019	20-03-30	CI
Knight Therapeutics Inc. announced Unified Tender Offer to acquire remaining 48.8% stake in Biotoscana Investments S.A. for approximately BRL 450 million.	19-12-19	CI
Knight Therapeutics Inc. completed the acquisition of 51.21% stake in Biotoscana Investments S.A. from Advent Cartagena S.a r.l., Essex Woodlands Health Ventures VIII, L.P., Essex Woodlands Health Ventures VIII-A, L.P. and Essex Woodlands Health Ventures VIII-B, L.P. managed by Essex Woodlands Management, Inc., MAZAL INVESTMENT VENTURES LTD., Robert Friedlander and Roberto Guttman.	19-11-28	CI
Biotoscana Investments S.A. Reports Earnings Results for the Third Quarter Ended September 30, 2019	19-11-12	CI
Biotoscana Investments S.A.‘s Equity Buyback announced on August 14, 2018, has expired with 1,346,300 shares, representing 1.31% for BRL 14.12 million.	19-10-30	CI
BIOTOSCANA INVESTMENTS S.A. Announces Change in Management	19-10-28	CI
Canada's Knight Therapeutics to acquire Biotoscana control by Nov 29: filing	19-10-28	RE
Biotoscana Investments S A : Knight Therapeutics to purchase Biotoscana in $281 million deal	19-10-21	RE
Knight Therapeutics Inc. entered into an agreement to acquire 51.21% stake in Biotoscana Investments S.A. from Advent Cartagena S.a r.l., Essex Woodlands Health Ventures VIII, L.P., Essex Woodlands Health Ventures VIII-A, L.P. and Essex Woodlands Health Ventures VIII-B, L.P. managed by Essex Woodlands Management, Inc., MAZAL INVESTMENT VENTURES LTD., Robert Friedlander and Roberto Guttman for approximately BRL 600 million.	19-10-20	CI
Biotoscana Confirms Divestiture Negotiations	19-10-09	CI
Biotoscana Investments S A : Knight Terapeutics and Eurofarma eye Biotoscana	19-10-07	RE
Biotoscana Investments S.A. Reports Earnings Results for the Second Quarter Ended June 30, 2019	19-08-12	CI
Tranche Update on Biotoscana Investments S.A.'s Equity Buyback Plan announced on August 14, 2018.	19-08-12	CI
EMS Is Reportedly Interested In Biotoscana	19-07-18	CI
Biotoscana Investments S.A. Reports Earnings Results for the First Quarter Ended March 31, 2019	19-05-13	CI
Tranche Update on Biotoscana Investments S.A.'s Equity Buyback Plan announced on August 14, 2018.	19-05-13	CI
Biotoscana Investments S.A. Reports Earnings Results for the Full Year Ended December 31, 2018	19-03-21	CI
Tranche Update on Biotoscana Investments S.A.'s Equity Buyback Plan announced on August 14, 2018.	19-03-21	CI
Tranche Update on Biotoscana Investments S.A.'s Equity Buyback Plan announced on August 14, 2018.	18-11-13	CI
Biotoscana Investments S.A. Announces Earnings Results for the Third Quarter of 2018	18-11-12	CI

Chart Biotoscana Investments S.A.

Duration

Period

More charts

Biotoscana Investments SA is a Luxembourg-based company engaged in the healthcare industry. The Company develops, manufactures and distributes pharmaceutical products. The Company offers drugs for the treatment of infectious and rare diseases, oncology, onco-hematology, special treatments and immunology, among others. Its product development pipeline is divided into two business models: partnership product development, which is focused on building relationships to license and commercialize products that are new to Latin America, and internal product development, which is focused on studying, designing, formulating and manufacturing branded generic products. Apart from the Luxembourg, the Company operates worldwide in a number of countries, including Peru, Argentina and Ecuador, among others.

Sector

Pharmaceuticals

More about the company

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
MERCK KGAA	+5.31%	70.44B
KYOWA KIRIN CO. LTD.	+10.97%	8.94B
SK BIOPHARMACEUTICALS CO., LTD.	-16.83%	4.75B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+43.48%	4.5B
YUHAN CORPORATION	+3.20%	3.85B
BETTA PHARMACEUTICALS CO., LTD.	-21.36%	2.34B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-29.67%	2.2B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+8.38%	1.96B
SUPERNUS PHARMACEUTICALS, INC.	+3.90%	1.65B

Specialty & Advanced Pharmaceuticals